Low AMH: What It Means for Your Fertility, and What It Doesn’t
A low AMH result is one of the most anxiety-provoking numbers in fertility medicine, and one of the most misunderstood. This guide explains precisely what the test can tell you, what it cannot, and how it should change your planning.
Direct answer: A low AMH means your ovaries hold fewer eggs than average for your age, it does not mean you cannot conceive. AMH predicts how your ovaries respond to IVF stimulation, not whether natural pregnancy will happen. What a low AMH truly changes is timing: decisions should be made earlier, and planned more precisely.
What AMH actually measures, and what it doesn’t
Anti-Müllerian hormone (AMH) is produced by the small, growing follicles in your ovaries. Because the number of these follicles broadly tracks the number of eggs remaining, a blood AMH level is used as a marker of ovarian reserve — the quantity of eggs left.
What AMH does not measure is egg quality, which depends far more on age than on any blood test. It also does not measure whether you ovulate, whether your tubes are open, or whether an embryo will implant. AMH is one input into a fertility plan, never the whole plan. If you haven’t yet read our primer on what AMH is and why it is tested, that is the natural starting point; this article is the next step: what to do when the number comes back low.
Why “low” needs context: age changes the meaning
AMH declines naturally with age, so the same value means different things at different ages. A level that is expected at 42 is unusual at 28. Laboratory assays also differ, and AMH can be transiently suppressed, for example by hormonal contraception, so a single surprising value deserves confirmation and interpretation by a clinician, not a conclusion drawn from a lab printout.
There is no single universal cut-off for “low”. Values below roughly 1.0–1.2 ng/mL are commonly described as reduced reserve, and very low values (below about 0.5 ng/mL) predict a limited response to ovarian stimulation. But these are planning thresholds, not verdicts on your ability to become a mother.
What a low AMH does not mean: your natural fertility
This is the single most important, and least known, fact about AMH. In a prospective cohort of 750 women aged 30–44 trying to conceive naturally, published in JAMA, women with low AMH (below 0.7 ng/mL) conceived at essentially the same rate over 6 and 12 cycles as women with normal AMH. The authors concluded that AMH should not be used to assess natural fertility in women without infertility (Steiner et al., JAMA 2017; PMID 29049585).
In plain terms: if you are conceiving on your own timeline, a low AMH does not by itself predict failure. Conception each month requires one good egg, not a large reserve. Where the reserve matters is when treatment, especially IVF — enters the picture, and in how much calendar time you can safely allow.
What a low AMH does change: your response to IVF stimulation
AMH is one of the two best predictors of how the ovaries respond to stimulation in an IVF cycle, the other being the antral follicle count (AFC) on ultrasound. The ESHRE guideline on ovarian stimulation makes a strong recommendation to use AMH or AFC, rather than older tests, to predict poor and high response (ESHRE Guideline Group, Hum Reprod Open 2020; PMID 32395637). A low AMH forecasts fewer eggs retrieved per cycle and a higher chance of cycle cancellation, while a high AMH warns of over-response and OHSS risk (La Marca et al., Hum Reprod Update 2010; PMID 19793843).
This is exactly why the test is valuable when used correctly: it lets your specialist individualise the protocol before the first injection — choosing the stimulation approach and dose to your ovaries rather than to an average patient. That is precision, and it is the correct use of AMH.
AMH and IVF success: it predicts eggs, not babies
It is tempting to read AMH as a success probability. The evidence says otherwise. A systematic review and meta-analysis of over 5,700 women found that AMH has only a weak association with live birth after IVF and “its predictive accuracy is poor” (Iliodromiti et al., Hum Reprod Update 2014; PMID 24532220). Women with low AMH have babies through IVF regularly; women with excellent AMH sometimes do not. Age and egg quality carry more of the outcome than the reserve number does.
At the same time, honesty matters: low AMH does mean fewer eggs per retrieval, which can mean more than one cycle is needed to reach the same goal. A realistic plan states this openly at the start rather than discovering it cycle by cycle.
Low AMH and endometriosis: why surgical decisions matter more
For women with endometriosis, particularly ovarian endometriomas — AMH carries an extra weight. Surgical excision of an endometrioma removes disease, but it also costs healthy ovarian tissue: a meta-analysis in the Journal of Clinical Endocrinology & Metabolism found a significant fall in AMH after endometrioma cystectomy (Raffi et al., JCEM 2012; PMID 22723324). Repeat ovarian surgery compounds that cost.
This is why, in our endometriosis programme, a low or falling AMH changes the sequencing question — should eggs or embryos be secured before surgery? Is this operation genuinely indicated now? — and why excision surgery in a woman who wants children is planned fertility-first, by a team that weighs the reserve cost of every ovarian step. The decision is rarely “surgery or not”; it is “in which order, and with what protection for your future options”.
When a low AMH changes the plan: four variables
In practice, we weigh a low AMH against four things together:
1. Age. The younger you are, the more a low AMH argues for acting early while egg quality is at its best, and the better the results of doing so.
2. How low, and how fast. A stable 1.1 ng/mL and a value that has halved in eighteen months are different situations. Trend sometimes matters more than a single number.
3. The rest of the fertility picture. Tubes, ovulation, semen analysis, uterus, a low AMH alongside another significant factor moves treatment forward in priority.
4. Your timeline and family goals. One child soon, or two children eventually? A low AMH mainly attacks the second pregnancy’s window, which is why we plan for the family you want, not just the next cycle.
When a low AMH should not rush you into IVF
A low AMH in a young woman with open tubes, regular ovulation, a normal semen analysis and time on her side is not an automatic IVF ticket, natural conception odds per month are not defined by the reserve. Equally, no supplement, injection or “ovarian rejuvenation” protocol has been shown to rebuild reserve; the ESHRE guideline recommends none of the commonly promoted adjuvants (DHEA, growth hormone, testosterone) for improving outcomes (PMID 32395637). Be sceptical of anyone selling AMH improvement. The honest levers are timing, protocol precision, and, where appropriate, preservation.
Fertility preservation: the option a low AMH puts on the table early
For women not ready for pregnancy, because of career, circumstance, a planned surgery, or endometriosis likely to need future intervention, a low AMH is the strongest argument for discussing egg or embryo freezing sooner rather than later. Preservation does not stop the biological clock, but it stores today’s egg quality for tomorrow’s decision. The conversation costs nothing; postponing it can cost options.
How we approach a low AMH at Balaji Horizon
Our IVF and reproductive medicine programme treats a low AMH as a planning input, not a prognosis. That means: confirming and interpreting the value in context; completing the full fertility picture before any treatment decision; individualising stimulation to your ovaries per current ESHRE evidence; sequencing surgery and IVF fertility-first when endometriosis is part of the story; and giving you realistic, number-honest counselling, including when the right advice is not to treat yet. Precision with judgment, applied to your goals rather than to a template.
When to test, when to re-test, and what to bring to a consult
AMH testing is reasonable when planning fertility treatment, before ovarian surgery, when endometriosis or family history raises concern about reserve, or when you are deciding how long you can safely wait. It can be drawn on any cycle day. If a result is unexpectedly low, re-testing after 2–3 months, off hormonal contraception where feasible, with an antral follicle count ultrasound gives a far steadier picture than one value alone. Bring previous reports: the trend is information.
Frequently asked questions
Does a low AMH mean I cannot get pregnant naturally?
No. In a large JAMA study of women aged 30–44 trying to conceive, low AMH did not reduce the chance of natural conception over 12 cycles. AMH predicts response to IVF stimulation, not natural fertility. What it does argue for is not delaying decisions unnecessarily.
What AMH level is considered low?
There is no single cut-off; values below roughly 1.0–1.2 ng/mL are usually called reduced, and below ~0.5 ng/mL predicts a limited IVF response. Age, the assay used, and hormonal contraception all affect interpretation, the number needs a clinician, not just a reference range.
Can supplements or injections increase my AMH?
No treatment has been shown to rebuild ovarian reserve. The ESHRE ovarian stimulation guideline recommends none of the commonly promoted adjuvants (DHEA, growth hormone, testosterone) for improving IVF outcomes. Small lab fluctuations after stopping the pill are not true increases.
Should I start IVF immediately because my AMH is low?
Not automatically. The decision weighs age, the trend of the value, the rest of your fertility work-up, and your family goals. A low AMH mainly shortens the safe waiting time, for some women the right step is IVF now; for others it is preservation, or a planned window of natural attempts.
Does endometriosis surgery lower AMH?
Excision of ovarian endometriomas measurably lowers AMH, and repeat ovarian surgery compounds the loss. If you have endometriosis and a low AMH, sequencing, whether to secure eggs or embryos before surgery, and whether surgery is genuinely indicated now, is the key conversation to have first.
References
- Steiner AZ et al. Association Between Biomarkers of Ovarian Reserve and Infertility Among Older Women of Reproductive Age. JAMA. 2017;318(14):1367–1376. PMID 29049585. DOI 10.1001/jama.2017.14588
- The ESHRE Guideline Group on Ovarian Stimulation. ESHRE guideline: ovarian stimulation for IVF/ICSI. Hum Reprod Open. 2020;2020(2):hoaa009. PMID 32395637. DOI 10.1093/hropen/hoaa009
- Iliodromiti S et al. The predictive accuracy of anti-Müllerian hormone for live birth after assisted conception: a systematic review and meta-analysis. Hum Reprod Update. 2014;20(4):560–570. PMID 24532220. DOI 10.1093/humupd/dmu003
- La Marca A et al. Anti-Müllerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update. 2010;16(2):113–130. PMID 19793843. DOI 10.1093/humupd/dmp036
- Raffi F, Metwally M, Amer S. The impact of excision of ovarian endometrioma on ovarian reserve: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2012;97(9):3146–3154. PMID 22723324. DOI 10.1210/jc.2012-1558
Medically reviewed by Dr. Priyadatt Patel, MBBS, MS — Senior Gynecologist · Advanced Laparoscopic Surgeon · IVF and Endometriosis Programme Lead. Last reviewed: 11 August 2026.
This article is educational and does not replace a medical consultation. Fertility decisions should be individualised with a qualified specialist who has your full clinical picture.
Free Patient Guide
The IVF Readiness Checklist
A clinically grounded primer covering AMH ranges, the cycle in plain terms, ten questions to ask, and honest international live-birth reference data by age band.
Get the guide →